Appendix.
Patient characteristics of the 3 study cohorts based on the different LVMi criteria as stratified by the extent of coronary artery plaque segments.
| LVM/BSAASE cohort | LVM/height2.7 cohort | LVM/BSACT cohort | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 segment | 1–4 segments | > 4 segments | p-value | 0 segment | 1–4 segments | > 4 segments | p-value | 0 segment | 1–4 segments | > 4 segments | p-value | |
| Demographics, n | 169 | 97 | 71 | 163 | 95 | 67 | 163 | 97 | 66 | |||
| Age, yrs | 47.3 ± 9.2 | 55.8± 10.4 | 61.1 ± 12.2 | <0.0001 | 47.1 ± 9.2 | 56.0 ± 10.4 | 61.2 ±12.2 | <0.0001 | 47.3 ± 9.2 | 55.9 ± 10.4 | 61.2 ± 12.3 | <0.0001 |
| Gender, male (%) | 92 (54.4%) | 62 (63.9%) | 52 (73.2%) | 0.005 | 88 (54.0%) | 60 (63.2%) | 48 (71.6%) | 0.01 | 89 (54.6%) | 62 (63.9%) | 47 (71.2%) | 0.01 |
| Race, black (%) | 18 (10.7%) | 11 (11.3%) | 1 (1.4%) | 0.05 | 18 (11.0%) | 9 (9.5%) | 0 (0%) | 0.01 | 18 (11.05) | 11 (11.3%) | 0 (0%) | 0.02 |
| Body mass index, kg/m2 | 28.6 ± 6.0 | 29.3 ± 5.8 | 29.3 ± 5.2 | 0.55 | 28.2 ± 5.6 | 29.0 ± 5.2 | 29.1 ± 5.2 | 0.38 | 28.5 ± 5.9 | 29.3 ± 5.8 | 29.3 ± 5.4 | 0.48 |
| Body surface area, m2 | 1.97 ± 0.26 | 2.00 ± 0.25 | 2.03 ± 0.27 | 0.19 | 1.96 ± 0.25 | 2.00 ± 0.25 | 2.03 ± 0.27 | 0.17 | 1.96 ± 0.26 | 2.01 ± 0.25 | 2.03 ± 0.27 | 0.15 |
| Risk factors | ||||||||||||
| Hypertension (%) | 40 (23.7%) | 42 (43.3%) | 45 (63.4%) | <0.0001 | 36 (22.1%) | 40 (42.1%) | 41 (61.2%) | <0.0001 | 37 (22.7%) | 42 (43.3%) | 42 (63.6%) | <0.0001 |
| Diabetes (%) | 10 (5.9%) | 10 (10.3%) | 13 (18.3%) | 0.004 | 9 (5.5%) | 10 (10.5%) | 10 (14.9%) | 0.02 | 9 (5.5%) | 10 (10.3%) | 10 (15.2%) | 0.02 |
| Hyperlipidemia (%) | 37 (21.9%) | 42 (43.3%) | 41 (57.8%) | <0.0001 | 33 (20.3%) | 41 (43.2%) | 40 (59.7%) | <0.0001 | 35 (21.5%) | 42 (43.3%) | 38 (57.6%) | <0.0001 |
| History of CAD (%) | 1 (0.6%) | 4 (4.1%) | 12 (16.9%) | <0.0001 | 1 (0.6%) | 4 (4.2%) | 12 (17.9%) | <0.0001 | 1 (0.6%) | 4 (4.1%) | 11 (16.7%) | <0.0001 |
| Family history of CAD (%) | 37 (21.9%) | 24 (24.7%) | 22 (31.0%) | 0.15 | 36 (22.1%) | 24 (25.3%) | 20 (29.9%) | 0.21 | 35 (21.5%) | 24 (24.7%) | 21 (31.8%) | 0.11 |
| History of LV dysfunction (%) | 1 (0.6%) | 2 (2.1%) | 3 (4.3%) | 0.05 | 1 (0.6%) | 2 (2.1%) | 3 (4.6%) | 0.05 | 1 (0.6%) | 2 (2.1%) | 3 (4.6%) | 0.05 |
| Smokers (%) | 71 (42.0%) | 52 (53.6%) | 46 (64.8%) | 0.0009 | 70 (42.9%) | 51 (53.7%) | 43 (64.2%) | 0.003 | 69 (42.3%) | 52 (53.6%) | 43 (65.2%) | 0.001 |
| Medications | ||||||||||||
| Aspirin (%) | 44 (26.0%) | 32 (33.0%) | 27 (38.0%) | 0.05 | 41 (25.2%) | 32 (33.7%) | 26 (38.8%) | 0.03 | 41 (25.2%) | 32 (33.0%) | 25 (37.9%) | 0.04 |
| Statin (%) | 27 (16.0%) | 29 (29.9%) | 35 (49.3%) | <0.0001 | 23 (14.1%) | 28 (29.5%) | 34 (50.8%) | <0.0001 | 25 (15.3%) | 29 (29.9%) | 33 (50.0%) | <0.0001 |
| Hypertensive Medication (%) | 38 (22.5%) | 42 (43.3%) | 45 (63.4%) | <0.0001 | 34 (20.9%) | 40 (42.1%) | 41 (61.2%) | <0.0001 | 35 (21.5%) | 42 (43.3%) | 42 (63.6%) | <0.0001 |
| Presenting Characteristics | ||||||||||||
| SBP, mmHg | 135 ± 20 | 142 ± 23 | 141 ± 24 | 0.02 | 135 ± 20 | 142 ± 23 | 139 ± 23 | 0.02 | 135 ± 20 | 142 ± 23 | 139 ± 23 | 0.03 |
| eGFR, ml/min/1.73 m2 | 87.3 ± 16.9 | 83.2 ± 18.3 | 79.8 ± 16.6 | 0.006 | 87.0 ± 17.0 | 82.8 ± 18.2 | 79.7 ± 17.0 | 0.01 | 87.1 ± 16.8 | 83.2 ± 18.3 | 79.2 ± 16.7 | 0.006 |
| CT Measurements | ||||||||||||
| LV ejection fraction, % | 68.4 ± 8.4 | 68.0 ± 8.8 | 66.4 ± 11.2 | 0.30 | 68.4 ± 8.5 | 67.8 ± 8.8 | 66.6 ± 11.3 | 0.38 | 68.5 ± 8.5 | 68.0 ± 8.8 | 66.7 ± 11.5 | 0.41 |
| RWT ratio | 0.35 ± 0.08 | 0.36 ± 0.08 | 0.37 ± 0.10 | 0.17 | 0.35 ± 0.08 | 0.36 ± 0.08 | 0.38 ± 0.10 | 0.18 | 0.35 ± 0.08 | 0.36 ± 0.08 | 0.37 ± 0.10 | 0.18 |